PharmaNet/i3 Named Distinguished Partner by US-China Anti-Cancer Group  
6/28/2012 10:29:15 AM

by Richard Daverman, PhD

June 27, 2012 -- PharmaNet/i3, the clinical-stage CRO division of inVentiv Health, received the Distinguished Partner Award from the US Chinese Anti-Cancer Association (USCACA) for its support of oncology clinical trials and cancer research in China. PharmNet/i3 has conducted 250 clinical trials in Asia and the Pacific Rim. The company has offices in Japan, Korea and China. More details....